Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Prostatic Neoplasms 121Neoplasm Metastasis 12Prostate Cancer Metastatic 4Oligometastatic Prostate Cancer 3Metastatic Hormone-sensitive Prostate Cancer (mHSPC) 3Metastatic Hormone-sensitive Prostate Cancer 3Adenocarcinoma 3Radiation Injuries 2Prostatic Diseases 2Prostate CA 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Neoplasms 2Metastatic Castration-resistant Prostate Cancer 2Urologic Diseases 1Urogenital Neoplasms 1Triple Negative Breast Neoplasms 1Stage IV Prostate Adenocarcinoma AJCC v7 1Stage I Prostate Adenocarcinoma 1Salivary Gland Neoplasms 1Recurrence 1Prostatic Neoplasms, Castration-Resistant 1Prostate Adenocarcinoma 1PSA Level Greater Than 0.03 1Oligorecurrent and Oligoprogressive Prostate Cancer Patients 1Non-metastatic, Hormone naïve Prostate Cancer 1Neoplasm Recurrence, Local 1Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) 1Metastatic Hormone-Sensitive Prostate Cance 1Metastatic Hormone Sensitive Prostate Cancer 1Metastatic Castration-sensitive Prostate Cancer 1

Interventions

Abiraterone Acetate 7enzalutamide 6olaparib 5Prednisone 5Pluvicto 5Docetaxel 5radium Ra 223 dichloride 4darolutamide 4cabazitaxel 3Prednisolone 3testosterone 17 beta-cypionate 2fludarabine 2abiraterone 2Nivolumab 2Cyclophosphamide 2Androgen Antagonists 2sipuleucel-T 1rucaparib 1poly ICLC 1pamiparib 1niraparib 1lactitol 1fludarabine phosphate 1fluciclovine F-18 1enfortumab vedotin 1ebastine 1copanlisib 1cabozantinib 1bempegaldesleukin 1avelumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Metastatic Castration-resistant Prostate Cancer × Androgen Antagonists × Clear all
NCT07476001 2026-05-15

Phase 2a Study of High-Dose Testosterone Followed by Radioligand Therapy in mCRPC

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Recruiting
12 enrolled
Genitourinary

Metastatic Castration-resistant Prostate Cancer

NCT07553988 2026-04-28

A Comparative Dose-finding Study of RS-113 in Patients With Metastatic Castration-resistant Prostate Cancer

R-Pharm

Phase 2 Active not recruiting
120 enrolled
Genitourinary

Metastatic Castration-resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡